title: [Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriacea].
abstract: BACKGROUND
  Ertapenem could be used to treat urinary tract infections (UTI) caused by ESBL producing enterobacteriacae (ESBL-E) and administered subcutaneously.
  
  
  METHODS
  The authors made a retrospective study on adult patients treated with ertapenem administered intravenously or subcutaneously for UTI caused by ESBL-E, between May 2009 and August 2011 at the Chambery hospital, France.
  
  
  RESULTS
  Twenty-five patients were treated (13 cases of prostatitis, ten of pyelonephritis, two of cystitis) mostly caused by Escherichia coli (24 cases). Subcutaneous injections were administered to 20 patients and 23 were treated through outpatient parenteral antibiotic therapy (OPAT). All patients were cured at the end of the ertapenem therapy. Urine samples collected during treatment for 12 patients were sterile. Three months after the end of the treatment, five patients had relapsed, and six had developed a UTI caused by another bacteria.
  
  
  CONCLUSIONS
  Ertapenem administered intravenously or subcutaneously could be an effective treatment for UTI caused by ESBL-E, especially using OPAT.
authors.affiliation: Service de Maladies Infectieuses, Centre Hospitalier de Chambéry, BP 1125, 73011 Chambéry, France. emmanuel.forestier@ch-chambery.fr
authors.forename: E
authors.initials: E
authors.lastname: Forestier
authors.forename: S
authors.initials: S
authors.lastname: Gros
authors.forename: D
authors.initials: D
authors.lastname: Peynaud
authors.forename: M
authors.initials: M
authors.lastname: Levast
authors.forename: D
authors.initials: D
authors.lastname: Boisseau
authors.forename: C
authors.initials: C
authors.lastname: Ferry-Blanco
authors.forename: A
authors.initials: A
authors.lastname: Labe
authors.forename: C
authors.initials: C
authors.lastname: Lecomte
authors.forename: O
authors.initials: O
authors.lastname: Rogeaux
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D004341:Drug Evaluation; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology*; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology; D029968:Escherichia coli Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007710:Klebsiella Infections / Q000188:drug therapy / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology; D011704:Pyelonephritis / Q000188:drug therapy* / Q000382:microbiology; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000032:analysis*; D047090:beta-Lactams / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D029968:Escherichia coli Proteins; D047090:beta-Lactams; D001618:beta-Lactamases; D000077727:Ertapenem